Phuturdex › Drugs › Bupivacaine
Drugs in development · updated 30 October 2026
Bupivacaine: clinical trials and development status
Other names and codes: Exparel, Sensorcaine, Xaracoll, Posimir, Marcaine, Marcaine Hydrochloride Preservative Free
As of 30 October 2026 Bupivacaine is in 63 active clinical trials (recruiting or ongoing, phases I–III) for 40 diseases. The most advanced phase is III.
Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Bupivacaine and get an email at every change or safety alert.
Sign in free →Diseases studied
For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov. Showing 30 of 40 diseases.
| Disease | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Postoperative pain | III | 16 | NCT07878156 |
| Agnosia | III | 6 | NCT07663435 |
| Migraine | III | 2 | NCT06937385 |
| Nephrolithiasis | III | 2 | NCT06349668 |
| Pain | III | 2 | NCT05964868 |
| Atrial fibrillation | III | 1 | NCT07893275 |
| Back pain | II–III | 1 | NCT06350981 |
| Breast neoplasm | III | 1 | NCT03351348 |
| Cleft palate | III | 1 | NCT04928352 |
| Digestive System Diseases | III | 1 | NCT03214510 |
| Gender dysphoria | III | 1 | NCT04979338 |
| Headache | III | 1 | NCT06937385 |
| Heart disease | II–III | 1 | NCT06077422 |
| Hemorrhage | II–III | 1 | NCT06456255 |
| Infratentorial neoplasm | III | 1 | NCT07878156 |
| Kidney neoplasm | III | 1 | NCT06349668 |
| Lung neoplasm | III | 1 | NCT06810375 |
| Paranasal sinus disease | II–III | 1 | NCT06456255 |
| Renal cell carcinoma | III | 1 | NCT07092566 |
| Tension headache | III | 1 | NCT06937385 |
| Ureteral neoplasm | III | 1 | NCT06349668 |
| Wrist Fractures | III | 1 | NCT06179004 |
| Chronic pain | II | 1 | NCT07839195 |
| Cluster headache | II | 1 | NCT04930887 |
| Duodenal neoplasm | II | 1 | NCT06411795 |
| Facial neuralgia | II | 1 | NCT04930887 |
| Facial pain | II | 1 | NCT04930887 |
| Joint Diseases | II | 1 | NCT07839195 |
| Pancreatic neoplasm | II | 1 | NCT06411795 |
| Paroxysmal hemicrania | II | 1 | NCT04930887 |
Everything on Bupivacaine
In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.
Open in Phuturdex →Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.